Released May 14, 2026, after the close
10-Q filed May 14, 2026, 44 days after period end · 0001193125-26-224170
Q1 2026 · 10-Q
Revenue$14.52M$14.52M −16.5% vs Q1 2025+24.7% vs Q4 2025
Net Income-$38.48M-$38.48M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$2.94-$2.94 N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$29,656,000N/M
Operating Cash Flow-$42,259,000N/M
Margins · derived
Operating margin-204.2%+189.6 pt vs Q1 2025
Net margin-265.0%+171.6 pt vs Q1 2025
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $14.52M | $17.40M | $13.01M | $12.67M |
| Net Income | -$38.48M | -$75.97M | -$58.21M | -$50.05M |
| EPS Diluted | -$2.94 | -$9.08 | -$0.59 | -$0.85 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR